Founded in 2021 in Shenzhen, China, CL Biologics (CLB) is a leading biologics contract development and manufacturing organization (CDMO). Led by an international team with extensive experiences in the biotech industry, CLB provides global biotech and biopharma clients with world-class facilities featuring the first 15kL bioreactors in China, robust process design, digital quality systems, and compliance with cGMP standards and global regulatory requirements. Currently CLB is building state-of-the-art CDMO plants in Shenzhen and Shanghai, with a total capacity of ~700 KL by 2024. CL Biologics, the World’s Local CDMO.

Mission

Change the world for the better, by providing affordable medicine to patients worldwide.

The CLB Shenzhen Headquarter